NASDAQ · Healthcare · Biotechnology
Vertex Pharmaceuticals Incorporated (VRTX)
As of Sep 25, 4:00 PM ET, Vertex Pharmaceuticals (VRTX) last traded at $526.19, up 0.73% on the day. Its TickerHum research score is 76/100 (above average). It reported revenue of $12.59B for the twelve months ending 2026-06-30, up 10.2% year over year, with a 38.0% operating margin.
Ratings
- Valuation: 52/100 — Strongest input: price / earnings (ttm) 30.6x. Weakest: free-cash-flow yield 2.8 %.
- Growth: 61/100 — Strongest input: diluted eps growth (ttm, yoy) +22.1 %. Weakest: revenue growth (ttm, yoy) +10.2 %.
- Profitability: 92/100 — Strongest input: operating margin 38.0 %. Weakest: return on equity 21.8 %.
- Financial health: 100/100 — Based on long-term debt / equity 0.01, current ratio 3.19, cash / long-term debt 58.51.
- Momentum: 70/100 — Strongest input: price vs 200-day average +11.5 %. Weakest: 3-month return +7.1 %.
- Attention: 51/100 — Strongest input: headlines in the last 7 days 31. Weakest: volume vs 3-month average 0.5x.
- Risk: 80/100 — Strongest input: max drawdown (1y) -15.2 %. Weakest: annualised volatility (1y) 28.5 %.
- Data confidence: 90/100 — Strongest input: latest financial period age (days) 59 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $12.59B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 10.2% | TTM ending 2026-06-30 · 10-Q |
| Net income | $4.41B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $17.17 | TTM ending 2026-06-30 · 10-Q |
| Operating margin | 38.0% | TTM ending 2026-06-30 · 10-Q |
| Net margin | 35.0% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $3.8B | TTM ending 2026-06-30 · 10-Q |
| Cash | $6.14B | as of 2026-06-30 · 10-Q |
| Long-term debt | $105M | as of 2011-09-30 · 10-Q |
| Debt / equity | 0.01 | as of 2011-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000875320).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.